Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.[1]

Listing of Claims

1. (Currently Amended) A method of preventing atherosclerosis in a mammal comprising administering to a mammal an effective amount of ~~a TNF-α inhibitor selected from the group consisting of~~:

a cyano ~~and~~ or carboxy derivatives of a substituted styrenes; a cyclic imides; a cycloalkyl amides ~~and~~ or cycloalkyl nitrites; an aryl amides; a 1-oxo-2-(2,6-dioxo-3-fluoropiperidin-3yl) isoindolines ~~and~~ or a 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidine-3-yl) isoindolines; a tetra substituted 2-(2,6-dioxopiperdin-3-yl)-1-oxoisoindolines; an imide/amide ethers ~~and~~ or alcohols; a succinimides ~~and~~ or a maleimides; a 1-oxo- ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring; an imido ~~and~~ or amido substituted alkanohydroxamic acids; a substituted phenethylsulfones substituted ~~to~~ on the phenyl group with an oxoisoindine group; a 1-~~Oxo~~ oxo ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines; a non-polypeptide cyclic amides; an imido ~~and~~ or amido substituted alkanohydroxamic acids; ~~and~~ or a substituted phenethylsulfones.

2. (Currently Amended) A method of preventing atherosclerosis in a mammal comprising administering to a mammal an effective amount of ~~a TNF-α inhibitor selected from the group consisting of~~: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline ~~and~~ or 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide.

3. Canceled without prejudice.

4. (Currently Amended) A method of treating atherosclerosis in a mammal comprising administering to a mammal in need thereof an effective amount of ~~a TNF-α inhibitor selected from the group consisting of~~:

a cyano ~~and~~ or carboxy derivatives of a substituted styrenes; a cyclic imides; a cycloalkyl amides ~~and~~ or cycloalkyl nitrites; an aryl amides; a 1-oxo-2-(2,6-dioxo-3-fluoropiperidin-3yl) isoindolines ~~and~~

[1] Certain claims were previously withdrawn from consideration, and an attempt to cancel one of them was refused in the Advisory Action. To avoid any confusion as to the pending claims, Applicant respectfully submits this listing of claims, which will replace all prior versions and listing of claims.

or a 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidine-3-yl) isoindolines; a tetra substituted 2-(2,6-dioxopiperdin-3-yl)-1-oxoisoindolines; an imide/amide ethers ~~and~~ or alcohols; a succinimides ~~and~~ or a maleimides; a 1-oxo- ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring; an imido ~~and~~ or amido substituted alkanohydroxamic acids; a substituted phenethylsulfones substituted ~~to~~ on the phenyl group with an oxoisoindine group; a 1-~~Oxo~~ oxo ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines; a non-polypeptide cyclic amides; an imido ~~and~~ or amido substituted alkanohydroxamic acids; ~~and~~ or a substituted phenethylsulfones.

5. (Currently Amended) A method of treating atherosclerosis in a mammal comprising administering to a mammal in need thereof an effective amount of ~~a TNF-α inhibitor selected from the group consisting of~~: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; ~~and~~ or 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide.

6. Canceled without prejudice.

7. (Currently Amended) The method of claims 1, 2, ~~3,~~ 4, or 5, ~~or 6~~ wherein the atherosclerosis is in the aorta, coronary artery, mesenteric arteries, or carotid arteries.

8. (Currently Amended) The method of claims 1, 2, ~~3,~~ 4, or 5, ~~or 6~~ wherein the atherosclerosis is in ~~the~~ a renal ~~arteries~~ artery.

9. (Currently Amended) The method of claims 1, 2, ~~3,~~ 4, or 5, ~~or 6,~~ wherein the mammal is a human.

10. (Currently Amended) The method of ~~any one of~~ claims 1, or 2, ~~or 3~~ wherein the mammal is a human at risk for complications of atherosclerosis.

11. (Currently Amended) The method of claim 10 wherein ~~the subject and~~ human has not undergone surgical vascular intervention.

12. (Currently Amended) The method of claims 1, 2, ~~3,~~ 4, or 5, ~~or 6~~ wherein approximately .01 mg/kg to 300 mg/kg of body weight is administered per day.

13. (Original) The method of claim 12 wherein approximately 0.1 mg/kg to 100 mg/kg of body weight is administered per day.

14. (Original) The method of claim 13 wherein approximately 0.5 mg/kg to 50 mg/kg of body weight is administered per day.

15. (Original) The method of claim 14 wherein approximately 1.0 mg/kg to 10 mg/kg of body weight is administered per day.

16. (Currently Amended) The method of claim 1, 2, ~~3,~~ 4, or 5, ~~or 6~~ wherein the ~~method of~~ administration is oral.

17. (Currently Amended) A method of inhibiting or preventing restenosis in a mammal comprising administering to a mammal in need thereof an effective amount of ~~a TNF-α inhibitor selected from the group consisting of~~:

a cyano ~~and~~ or carboxy derivatives of a substituted styrenes; a cyclic imides; a cycloalkyl amides ~~and~~ or cycloalkyl nitrites; an aryl amides; a 1-oxo-2-(2,6-dioxo-3-fluoropiperidin-3yl) isoindolines ~~and~~ or a 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidine-3-yl) isoindolines; a tetra substituted 2-(2,6-dioxopiperdin-3-yl)-1-oxoisoindolines; an imide/amide ethers ~~and~~ or alcohols; a succinimides ~~and~~ or a maleimides; a 1-oxo- ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring; an imido ~~and~~ or amido substituted alkanohydroxamic acids; a substituted phenethylsulfones substituted ~~to~~ on the phenyl group with an oxoisoindine group; a 1-~~Oxo~~ oxo ~~and~~ or 1,3 dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines; a non-polypeptide cyclic amides; an imido ~~and~~ or amido substituted alkanohydroxamic acids; ~~and~~ or a substituted phenethylsulfones.

18. (Currently Amended) A method of inhibiting or preventing restenosis in a mammal comprising administering to a mammal in need thereof an effective amount of ~~a drug selected from the group consisting of~~: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; ~~and~~ or 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide so that restenosis is prevented or reduced.

19. Canceled without prejudice.

20. (Original) The method of claim 17 wherein approximately .01 mg/kg to 300 mg/kg of body weight administered per day.

21. (Original) The method of claim 20 wherein approximately 0.1 mg/kg to 100 mg/kg of body weight is administered per day.

22. (Original) The method of claim 21 wherein approximately 0.5 mg/kg to 50 mg/kg of body weight is administered per day.

23. (Original) The method of claim 22 wherein approximately 1.0 mg/kg to 10 mg/kg of body weight is administered per day.

24. (Currently Amended) The method of claims 17~~,~~ or 18 ~~or 19~~ wherein the treatment begins prior to surgical intervention.

25. (Original) The method of claim 24 wherein treatment begins prior to surgical intervention and is continued for about 4 to 12 weeks after the surgical intervention.

26. (Original) The method of claim 24 wherein the treatment begins about 12 hours or less prior to scheduled intervention.

27. (Original) The method of claim 25 wherein the treatment begins about 12 hours or less prior to scheduled intervention.

28. (Original) The method of claim 24 wherein the surgical intervention is percutaneous coronary intervention, percutaneous transluminal coronary angioplasty, carotid percutaneous transluminal angioplasty coronary by-pass grafting or coronary angioplasty with stent implantation.

29. (Original) The method of claim 24 wherein the surgical intervention is renal angioplasty, peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries or surgical intervention using impregnated artificial grafts.

30. (Currently Amended) The method of claims 17~~,~~ or 18, ~~or 19~~ wherein the surgical intervention is unscheduled and treatment begins at the time of surgery.

31. (Currently Amended) The method of claims 17~~,~~ or 18, ~~or 19~~ wherein the surgical intervention is unscheduled and treatment begins at the time of surgery and is discontinued about 4 to 12 weeks after the surgical intervention.

32-42. Previously canceled without prejudice.

43. (Currently Amended) The method of claim 10 wherein the human has one or more of the following conditions: abnormal serum lipid levels, hypertension, cigarette smoking, diabetes mellitus, obesity, physical inactivity, hyperhomocysteinemia ~~and~~ or chlamydia pneumoniae infection.

44. (Currently Amended) The method of claims 1, 2, ~~3,~~ 4, or 5, ~~or 6~~ wherein the atherosclerosis is in the common iliac arteries, internal iliac arteries, external iliac arteries, or the pulmonary arteries.